Cargando…

Netarsudil monotherapy as the initial treatment for open-angle glaucoma and ocular hypertension in Indian patients: A real-world evaluation of efficacy and safety

PURPOSE: Glaucoma is the second leading cause of blindness worldwide, affecting more than 64 million people aged 40–80. The best way to manage primary open-angle glaucoma (POAG) is by lowering the intraocular pressure (IOP). Netarsudil is a Rho kinase inhibitor, the only class of antiglaucoma medica...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathur, Manoj Chandra, Ratnam, P. Venkat, Saikumar, S.J., John, Manuel, Ravishankar, Siddharth, Dinesh, M.B, Chandil, Priya, Pahuja, Kishore, Cherlikar, Vidya, Wadhwani, Sunny, Bendale, Pankaj, Hazari, Ajit, Mishra, Rajesh, Deshmukh, Susheel, Achlerkar, Rahul Raja, Shah, Devang Tilak, Hingorani, Chanda, Shah, Kaivan, Topiwala, Pratik, Jani, Sheetal, Rana, Viral G., Majumdar, Nilay Kumar, Chakrabarti, Debasis, Dey, Rituparna, Halder, Debabrata, Choudhury, Sumit, Kumar, Ajeet, Das, Sasmita, Nanda, Ashok Kumar, Kumar, Vidya Bhushan, Dubey, Rama, Kamdar, Gulam Ali, Pandey, Alka, Kishanpuria, Sheetal, Srivastava, Rajat Mohan, Singh, Parul, Verma, Sunil Kumar, Sharma, Neha, Gupta, Rajeev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418014/
https://www.ncbi.nlm.nih.gov/pubmed/37322670
http://dx.doi.org/10.4103/IJO.IJO_25_23
Descripción
Sumario:PURPOSE: Glaucoma is the second leading cause of blindness worldwide, affecting more than 64 million people aged 40–80. The best way to manage primary open-angle glaucoma (POAG) is by lowering the intraocular pressure (IOP). Netarsudil is a Rho kinase inhibitor, the only class of antiglaucoma medications that reorganizes the extracellular matrix to improve the aqueous outflow through the trabecular pathway. METHODS: An open-label, real-world, multicentric, observation-based 3-month study was performed for assessing the safety and ocular hypotensive efficacy of netarsudil ophthalmic solution (0.02% w/v) in patients with elevated IOP. Patients were given netarsudil ophthalmic solution (0.02% w/v) as a first-line therapy. Diurnal IOP measurements, best-corrected visual acuity, and adverse event assessments were recorded at each of the five visits (Day-1: screening day and first dosing day; subsequent observations were taken at 2 weeks, 4 weeks, 6 weeks, and 3 months). RESULTS: Four hundred and sixty-nine patients from 39 centers throughout India completed the study. The mean IOP at baseline of the affected eyes was 24.84 ± 6.39 mmHg (mean ± standard deviation). After the first dose, the IOP was measured after 2, 4, and 6 weeks, with the final measurement taken at 3 months. The percentage reduction in IOP in glaucoma patients after 3 months of once-daily netarsudil 0.02% w/v solution use was 33.34%. The adverse effects experienced by patients were not severe in the majority of cases. Some adverse effects observed were redness, irritation, itching, and others, but only a small number of patients experienced severe reactions, as reported in a decreasing order: redness > irritation > watering > itching > stinging > blurring. CONCLUSION: We found that netarsudil 0.02% w/v solution monotherapy when used as the first-line treatment in primary open-angle glaucoma and ocular hypertension was both safe and effective.